Cullinan Therapeutics, Inc. (CGEM)
21.82
+0.14
(+0.65%)
USD |
NASDAQ |
Aug 24, 16:00
21.85
+0.03
(+0.14%)
After-Hours: 20:00
Cullinan Therapeutics Shareholders Equity (Quarterly) : 321.75M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 321.75M |
| March 31, 2026 | 366.17M |
| December 31, 2025 | 408.73M |
| September 30, 2025 | 451.37M |
| June 30, 2025 | 492.15M |
| March 31, 2025 | 551.84M |
| December 31, 2024 | 590.33M |
| September 30, 2024 | 627.86M |
| June 30, 2024 | 656.22M |
| March 31, 2024 | 425.66M |
| December 31, 2023 | 453.70M |
| September 30, 2023 | 468.82M |
| June 30, 2023 | 499.57M |
| March 31, 2023 | 485.65M |
| Date | Value |
|---|---|
| December 31, 2022 | 535.03M |
| September 30, 2022 | 586.13M |
| June 30, 2022 | 604.54M |
| March 31, 2022 | 418.70M |
| December 31, 2021 | 424.97M |
| September 30, 2021 | 443.39M |
| June 30, 2021 | 455.55M |
| March 31, 2021 | 466.90M |
| December 31, 2020 | 200.31M |
| September 30, 2020 | 89.51M |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 97.86M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Rallybio Corp. | 94.50M |
| MapLight Therapeutics, Inc. | 348.30M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 363.79M |
| Total Liabilities (Quarterly) | 42.03M |
| Debt to Equity Ratio | 0.0064 |
| Current Ratio | 8.417 |
| Net Debt Paydown Yield | -0.00% |